GWPH Stock: Receives Favorable Results from Epidiolex Trials

GWPH Stock

GW Pharmaceuticals, the company behind the first FDA approved cannabis medicine Epidiolex, brought excitement to the market yesterday. It announced a successful trial of Epidiolex and further proved the medication’s ability to treat two rare forms of epilepsy. GWPH stock was up over 4% as a result.

GWPH Stock

The news sent GWPH stock on an upward trajectory, and at the height, it was selling for $133.00 USD. Today, however, the company has lost most of those gains, opening at $126.80. Perhaps some investors took advantage of the short-term price hike and quickly sold at the height. 

However, the news is sure to affect GWPH stock in the long-term, as the trial met its objective of reducing convulsive seizures in patients with two dose levels, 10mg and 20mg a day. This is big news for the company and for the drug in question, Epidiolex.

As CEO of the Epilepsy Foundation, Philip M. Gattone puts it:

Capitalize off Cannabis
Sign up now to start receiving our investing insights for FREE!


“The positive results from this latest EPIDIOLEX clinical trial are very encouraging for those living with intractable seizures caused by LGS and Dravet syndrome, two extremely difficult treatment-resistant forms of epilepsy.”

In Detail 

GW Pharmaceuticals (NASDAQ:GWPH) ran the study over a 14-week period. The results showed a dramatic reduction of seizures in patients, including a 46% decrease for those on the 20mg dose, and a 49% decrease for those on the 10mg dose.

>> Cannabis Penny Stocks Up and Down Today

According to the principal investigator of the trail Ian Miller MD:

“The positive outcome in this second trial of EPIDIOLEX in patients with Dravet syndrome further reinforces the effectiveness of this newly available medicine in this particularly difficult to treat, childhood-onset epilepsy.”

GWPH Stock: Q4 Earnings Release

GW Pharmaceuticals’ Q4 earnings release is expected later today. It is projected that the results will show a loss of $2.46 per share on sales of $5.48 million.

In Q4 2017, recorded sales totaled $2.86 million. However, this year, revenue is predicted to have grown over 90%. Despite this, GWPH stock is down 1.84% on the year. 

Featured Image: Depositphotos/© Wavebreakmedia

If You Liked This Article Click To Share